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ADCC = antibody-dependent, cell-mediated cytotoxicity; DCIS = ductal carcinoma in situ; EGFR = epidermal growth factor receptor; FISH = 
fluorescence in situ hybridization; PI3K = phosphoinositide 3-kinase.
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Introduction
The HER2/Neu proto-oncogene product is a member of
the erbB family of transmembrane receptor tyrosine
kinases, which also includes the epidermal growth factor
receptor (EGFR, HER1, ErbB1), HER3 (ErbB3), and
HER4 (ErbB4). Except for HER2, binding of receptor-spe-
cific ligands to the extracellular domain of EGFR, HER3,
and HER4 results in the formation of homodimeric and
heterodimeric phosphorylated, kinase-active complexes
into which HER2 is recruited as a preferred partner [1–3].
Even though HER2 is unable to interact directly with HER-
activating ligands, it can potentiate signaling by its co-
receptors and/or increase the binding affinity of ligands to
EGFR and HER3 (reviewed in [1]). Studies with HER2-
overexpressing breast cancer cell lines and human tumors
have shown constitutive phosphorylation of HER2 [4,5].
The biochemical basis for this activation is not clear but it
is consistent with the ability of wild-type Neu, the rat
homolog of human HER2, to multimerize and become acti-
vated in a ligand-independent fashion when present in
cells at high density [6]. Overexpression of HER2 is asso-
ciated with transformation of mammary epithelial cells
[7,8] as well as shorter survival in patients with breast car-
cinoma [9,10]. The association of HER2 with poor patient
prognosis, the ability to measure HER2 levels prospec-
tively in diagnostic tumor tissue, and the lack of an appar-
ent physiological role of HER2 in the adult, initially
suggested this receptor as a rational therapeutic target in
human breast cancer.
Herceptin: mechanisms of action and clinical
activity
One therapeutic approach against HER2-overexpressing
breast cancers is the generation of Herceptin
(trastuzumab), a humanized IgG1 that binds to residues
529–626 in the HER2 ectodomain [11]. The mouse
hybridoma counterpart of Herceptin, 4D5, partly removes
HER2 from the plasma membrane [12,13] and/or
induces HER2 homodimerization (CL Arteaga, unpub-
lished data), potentially preventing HER2 molecules from
interacting with other HER co-receptors and thus impair-
ing the growth of HER2-dependent tumor cells. A recent
study demonstrated that Herceptin blocks the metallo-
protease-induced cleavage of HER2 [14]. Proteolytic
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cleavage of HER2 results in the generation of a 95kDa
amino-terminal membrane-associated fragment and
shedding of the receptor’s ectodomain [15]. The consti-
tutive kinase activity of the 95kDa cytoplasmic fragment
and the association of high levels of the shed HER2
ectodomain with poor patient outcome [16,17] suggest
that cleavage of HER2, potentially blocked by Herceptin,
might be of clinical significance. Clynes and colleagues
[18] reported that the inhibitory effect of the antibody
against HER2-dependent xenografts is markedly abro-
gated in mice lacking the receptor FcγRIII, strongly imply-
ing that antibody-dependent, cell-mediated cytotoxicity
(ADCC) is the predominant mechanism of action of the
humanized IgG1. More recently, Yakes and colleagues
[19] reported that, in HER2-overexpressing tumor cells,
treatment with Herceptin results in inhibition of phospho-
inositide 3-kinase (PI3K) and the serine/threonine kinase
Akt. In that study, the antitumor effect of Herceptin was
reversed by forced expression of activated Akt, suggest-
ing that, in addition to immune mechanisms, the antibody
might exert its antitumor effect by a blockade of PI3K/Akt
signaling.
Although the mechanisms of action of Herceptin against
patients’ tumors remain to be elucidated, it has been
shown to induce tumor regressions in up to 20% of
heavily pretreated metastatic breast cancers [20,21].
Vogel and colleagues [22] recently reported the results of
a clinical trial of single-agent Herceptin used as first-line
therapy in 111 patients with metastatic breast tumors with
high levels of HER2. Clinical responses were limited to
tumors exhibiting HER2 overexpression or HER2 gene
amplification as determined by 3+ immunohistochemistry
or excess copies of HER2 by fluorescence in situ
hybridization (FISH), respectively. In this cohort, the objec-
tive response rate and the clinical benefit rate, as defined
by stable disease lasting longer than 6 months, were a
robust 35% and 48%, respectively [22]. Although an
accurate assessment of the median duration of clinical
response was not possible because of patient censoring,
57% of the responding patients were free of disease pro-
gression at more than 12 months of follow-up, underscor-
ing the durability of the responses. Remarkably, the
median duration of survival for all enrolled patients was
24.4 months, almost identical to the 25.1 months median
survival of patients with HER2-overexpressing metastatic
breast tumors treated with chemotherapy and Herceptin in
a previous study [23]. Taken together, these clinical data
confirm a role for HER2 in the progression of human
breast carcinomas. They also suggest that a cohort of
breast cancers remain HER2-dependent until advanced
metastatic phases of the disease. In addition, high levels
of HER2 protein overexpression and/or HER2 gene ampli-
fication accurately predict reasonable odds of response to
Herceptin and can therefore be used for rational patient
selection with this molecule-directed therapy.
Rationale for future clinical directions
The rate of HER2 gene amplification in ductal carcinoma
in situ (DCIS) of the breast is the same as or higher than
that in metastatic breast cancer [24–26]. Because DCIS
is a well-established precursor of invasive breast cancer
[27], this suggests that HER2 overexpression occurs
years before the onset of advanced invasive carcinoma.
The progression of DCIS to invasive and late metastatic
cancer is inexorably associated with the accumulation of
additional genetic alterations. On the basis of these data,
one could speculate on two possibilities. First, the results
of the study by Vogel and colleagues [22] might be better
than could have been expected as they suggest that a
cohort of metastatic breast cancers, namely the Herceptin
responders, remain predominantly dependent on HER2
function until late phases in the natural history of the
disease. Such a magnitude of clinical response might not
necessarily apply to the inactivation of other cancer
targets with single molecular therapies. Second, it would
be expected that the efficacy and curative potential of Her-
ceptin would increase if used in earlier phases of the
disease and/or in patients with lower tumor burden, that is,
for the prevention of progression of preinvasive cancers or
for the treatment of subclinical micrometastases in the
adjuvant setting. Several clinical trials with Herceptin in
the adjuvant setting in HER2-overexpressing breast
cancers are under way worldwide. It is envisaged that
enrollment into these large adjuvant trials and the potential
general use of Herceptin in the adjuvant setting will
change the natural history of HER2-amplified breast carci-
noma. As these trials continue to enroll patients, one could
expect a decrease in the overall percentage of metastatic
breast tumors diagnosed de novo that express high levels
of the proto-oncogene.
Slamon and colleagues [23] reported the ability of Her-
ceptin to increase the clinical benefit from first-line
chemotherapy against metastatic breast cancers that
overexpress HER2. These ground-breaking studies docu-
mented a 25% improvement in survival in patients that
received concurrent Herceptin and chemotherapy com-
pared with chemotherapy alone. Interestingly, however,
the median survival (25.1 months) of patients in this trial
receiving the combination was almost identical to the
24.4-month median survival of patients enrolled in the
single-agent Herceptin trial performed by Vogel and col-
leagues [22]. In both of these studies, the eligibility was
similar whereas Herceptin was much better tolerated in
the single-agent trial than was the combination of
chemotherapy plus antibody in the study by Slamon and
colleagues. Although one cannot exclude referral biases
that might have resulted in different patient populations in
these two trials, the published demographics for the sub-
jects enrolled in these studies indicate that they were
similar when compared by age, performance status, per-
centage of steroid receptor-positive tumors, number of98
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metastatic sites, and prior adjuvant chemotherapy. If these
HER2-overexpressing patient cohorts were similar, as the
patients’ published characteristics would support, this
might suggest, first, that in the combination therapy study
the antitumor effect was mainly due to Herceptin, and,
second, that Herceptin is a reasonable first-line single
agent in oligosymptomatic patients that fit the eligibility of
the study by Vogel and colleagues and can be used as a
platform onto which other molecular therapies, not neces-
sarily chemotherapy, can be added. Those added thera-
pies would be those that target molecules or mechanisms
of de novo or acquired Herceptin resistance.
Therapeutic resistance
Most metastatic breast tumors with HER2 gene amplifica-
tion and/or very high levels of HER2 protein do not
respond to Herceptin, suggesting the possibility that in
most late breast cancers, HER2 has become dispensable
for tumor viability and progression. This fact, together with
the frequent overexpression of HER2 in non-invasive
disease and the eventual escape from Herceptin action in
patients with HER2-amplified metastatic breast cancers,
suggests de novo and acquired mechanisms of therapeutic
resistance. The antitumor effect of HER2 inhibitors such as
Herceptin would require the subversion of key post-recep-
tor signaling pathways and cell cycle/anti-apoptosis regula-
tory molecules that mediate the transforming effects of
HER2. These post-receptor pathways are shared with het-
erologous receptor networks [28,29] and/or with het-
erodimers of the same HER (ErbB) network that are not
affected by Herceptin. These data therefore imply that
tumor cells are intrinsically endowed with signaling mecha-
nisms of compensation that can counteract the blockade of
HER2 function by single-agent Herceptin.
The mechanisms of de novo or acquired resistance to
Herceptin are not yet known. However, recent reports
suggest some possibilities. Indeed, overexpression of the
IGF-I receptor abrogates the effect of Herceptin against
HER2-overexpressing SKBR-3 cells. Addition of the IGF-I
receptor antibody αIR3 or IGF-BP3 reverses Herceptin
resistance [30]. Herceptin potently inhibits PI3K and Akt
in HER2-dependent, antibody-sensitive cells [19,31].
Conversely, Herceptin neither decreases PI3K activity nor
inhibits the growth of HER2-overexpressing MKN gastric
cancer cells [32]. Transduction of vectors encoding acti-
vated Akt prevents the Herceptin-induced inhibition of pro-
liferation of BT-474 cells and apoptosis in SKBR-3 cells
[19]. These data suggest that inhibition of PI3K/Akt signal-
ing is required for the antitumor effect of HER2 inhibitors
such as Herceptin. Many breast cancers harbor genetic
alterations resulting in aberrant PI3K/Akt signaling or over-
express heterologous receptor networks, such as IGF-IR,
that potently activate PI3K/Akt. We speculate that these
coexisting alterations in HER2-overexpressing breast
cancers dampen or abrogate Herceptin action. On the
basis of these data, a combined therapeutic approach
with HER2 and PI3K/Akt inhibitors would be worth investi-
gating in these tumors.
High levels of activated EGFR abrogate the efficacy of Her-
ceptin against HER2-gene-amplified cancer cells [32] and
this resistance is reversed by ATP-competitive inhibitors of
the EGFR tyrosine kinase [33]. In addition, the EGFR anti-
body C225 synergizes with 4D5 against HER2-overex-
pressing ovarian cancer cells [34]. Moreover, the EGFR
kinase inhibitor ZD1839 inhibits HER2 phosphorylation by
itself and potentiates the antitumor effect of Herceptin
against breast cancer xenografts [35–37]. Taken together
these results suggest, first, that activated EGFR can poten-
tially mediate escape from Herceptin action, and second,
that combinations of Herceptin with EGFR inhibitors are
synergistic against HER2-overexpressing tumors that also
express EGFR. This hypothesis is currently being tested in
phase II studies of Herceptin in combination with the EGFR
kinase inhibitors ZD1839 or OSI-774.
Another approach that might shed light on mechanisms of
Herceptin resistance is the sequencing of the HER2 gene
from tumors known to be progressing on Herceptin
therapy. It should be emphasized that the studies docu-
menting a lack of somatic mutations of HER2 in primary
breast cancers [38] predate the development and use of
Herceptin. Thus, the possibility of acquired HER2 muta-
tions as a result of the selective pressure of HER2 block-
ade has never been explored and is worth revisiting in
breast cancers ‘selected’ for Herceptin resistance in vivo.
Finally, one possible exploratory trial design to address
resistance mechanisms would be the administration of
neoadjuvant Herceptin followed by chemotherapy to newly
diagnosed HER2 gene-amplified tumors. Herceptin can be
started as a single agent for the first 4 weeks before the
addition of chemotherapy, while tumor core biopsies are
obtained weekly. This approach has been used effectively
with antiestrogens. These studies have shown that as little
as 14 days of therapy with tamoxifen results in a marked
reduction of breast cancer cell proliferation as measured
by Ki67 immunohistochemistry of tumor sections but this
reduction was limited to estrogen-receptor-positive tumors
[39–41]. Any excess tissue from the initial and follow-up
core biopsies can be used to detect novel RNAs or pro-
teins and their changes as a function of inhibition of cell
proliferation and/or inhibition of cell survival after treatment
with Herceptin. These two endpoints will be measured by
Ki67 immunohistochemistry and TUNEL (terminal trans-
ferase deoxytidyl uridine end labeling), respectively. By
focusing on differences in dynamic changes on RNA
and/or protein expression profiles between responders and
non-responders, this approach should detect markers of
resistance to Herceptin and/or mechanisms causally asso-
ciated with the resistant phenotype.99
Summary
The data summarized above clearly imply that Herceptin is
an effective first-line single-agent therapy for HER2-over-
expressing metastatic breast cancers. Herceptin can be
used as a platform onto which other molecular therapies,
perhaps those targeting molecules that mediate de novo
or acquired escape from the HER2 inhibitor, can be
added. Because Herceptin is well tolerated, scientifically
rational combinations of the antibody with other molecule-
targeted drugs are medically justifiable as first-line therapy
in metastatic disease. Whether giving Herceptin alone as
initial therapy jeopardizes subsequent survival in response
to treatment with Herceptin and chemotherapy requires
further investigation. Elucidation of the preferential molec-
ular mechanisms of escape from Herceptin and/or HER2
dependence will define new rational targets against which
drugs either are available or are to be developed. Drugs
against these targets can be combined with Herceptin to
prevent de novo or acquired resistance and to enhance
therapeutic efficacy. If tumor-specific and well tolerated,
combinations of anti-signaling drugs that include Her-
ceptin should become a robust therapeutic alternative to
non-specific cytotoxic chemotherapy against HER2-over-
expressing breast carcinoma.
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